胰高血糖素样肽-1受体激动剂逆转糖尿病周围神经病变的神经形态学异常
本研究对22例连续招募的2型糖尿病受试者在开始胰高血糖素样肽-1受体激动剂(GLP-1 RA,司美格鲁肽或度拉糖肽)治疗前及治疗1个月后,采用周围神经超声测量胫神经横截面积并结合神经病变症状评分和神经传导检查评估神经结构。治疗前81.8%的受试者神经尺寸病理性增大,治疗1个月后86%的受试者神经尺寸改善(p<0.05),32%恢复至正常神经形态。3个月随访研究(n=14)显示93%的受试者神经尺寸进一步改善,伴随神经病变严重程度降低(p<0.05)和腓肠感觉神经传导波幅改善(p<0.05)。
要点
- 治疗前81.8%的2型糖尿病受试者存在神经尺寸病理性增大。
- GLP-1 RA治疗1个月后86%的受试者神经尺寸改善,32%恢复至正常神经形态。
- 3个月随访时93%的受试者神经尺寸进一步改善,伴神经病变严重程度降低和腓肠感觉神经传导波幅改善。
核心结论
- 本研究证明GLP-1 RA在改善神经病变结局方面有效,证据主要来自结构和形态学指标的改善,并得到电生理和临床终点的支持。
- 未来需要纳入定量感觉测试和表皮内神经纤维密度测量的研究来探讨对小纤维功能和结构的益处。
研究设计与样本
- 采用周围神经超声测量胫神经横截面积,结合经验证的神经病变症状评分和神经传导检查评估神经结构。
- 连续招募22例2型糖尿病受试者,在开始GLP-1 RA(司美格鲁肽或度拉糖肽)治疗前和治疗1个月后进行评估。
- 另进行3个月随访研究(n=14)。
主要发现
- 治疗前81.8%的受试者(n=22)存在神经尺寸病理性增大。
- 治疗1个月随访时86%的受试者神经尺寸改善(p<0.05),32%恢复至正常神经形态。
- 3个月随访研究(n=14)显示93%的受试者神经尺寸进一步改善,伴随神经病变严重程度降低(p<0.05)和腓肠感觉神经传导波幅改善(p<0.05)。
局限性
- 未来需要纳入定量感觉测试和表皮内神经纤维密度测量的研究来探讨对小纤维功能和结构的益处。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetic peripheral neuropathy (DPN) is a highly prevalent cause of physical disability. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used to treat type 2 diabetes and animal studies have shown that glucagon-like peptide-1 (GLP-1) receptors are present in the central and peripheral nervous systems. This study investigated whether GLP-1 RAs can improve nerve structure. METHODS: Nerve structure was assessed using peripheral nerve ultrasonography and measurement of tibial nerve cross-sectional area, in conjunction with validated neuropathy symptom scores and nerve conduction studies. A total of 22 consecutively recruited participants with type 2 diabetes were assessed before and 1 month after commencing GLP-1 RA therapy (semaglutide or dulaglutide). RESULTS: There was a pathological increase in nerve size before treatment in 81.8% of the cohort (n=22). At 1 month of follow-up, there was an improvement in nerve size in 86% of participants (p<0.05), with 32% returning to normal nerve morphology. A 3 month follow-up study (n=14) demonstrated further improvement in nerve size in 93% of participants, accompanied by reduced severity of neuropathy (p<0.05) and improved sural sensory nerve conduction amplitude (p<0.05). CONCLUSIONS/INTERPRETATION: This study demonstrates the efficacy of GLP-1 RAs in improving neuropathy outcomes, evidenced by improvements in mainly structural and morphological measures and supported by electrophysiological and clinical endpoints. Future studies, incorporating quantitative sensory testing and measurement of intraepidermal nerve fibre density, are needed to investigate the benefits for small fibre function and structure.
引用
- Dhanapalaratnam R, Issar T, Lee ATK, et al. Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy. Diabetologia. 2024. PMID: 38189936. doi:10.1007/s00125-023-06072-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。